Differential Methylation as a Biomarker of Response to Etanercept in Patients with Rheumatoid Arthritis

Arthritis and Rheumatology

Volumn 68, Issue 6, 2016, Pages 1353-1360

  Plant, Darren ^a   Webster, Amy ^b   Nair, Nisha ^b   Oliver, James ^b   Smith, Samantha L ^b   Eyre, Steven ^b   Hyrich, Kimme L ^b   Wilson, Anthony G ^c   Morgan, Ann W ^d   Isaacs, John D ^e   Worthington, Jane ^b   Barton, Anne ^b  

^a MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY COLLEGE DUBLIN   (Ireland)

^d UNIVERSITY OF LEEDS   (United Kingdom)

^e NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; METHOTREXATE; TUMOR NECROSIS FACTOR; ANTIRHEUMATIC AGENT; BIOLOGICAL MARKER;

ADULT; ARTICLE; BLOOD SAMPLING; CHROMOSOME 4; CONTROLLED STUDY; DNA METHYLATION; EPIGENETICS; EXON; FEMALE; GENE; GENE MAPPING; GENETIC MARKER; GENOME ANALYSIS; HUMAN; LRPAP1 GENE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; ARTHRITIS, RHEUMATOID; GENETICS; MIDDLE AGED; TREATMENT OUTCOME;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOMARKERS; DNA METHYLATION; ETANERCEPT; FEMALE; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84964323942     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39590     Document Type: Article

References (38)

1. Gaffo A, Saag KG, Curtis JR., Treatment of rheumatoid arthritis. Am J Health Syst Pharm 2006; 63: 2451-65.
2. Soubrier M, Lukas C, Sibilia J, Fautrel B, Roux F, Gossec L, et al., Disease activity score-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis: data from the GUEPARD trial and ESPOIR cohort. Ann Rheum Dis 2011; 70: 611-5.
3. Heiberg MS, Nordvag BY, Mikkelsen K, Rodevand E, Kaufmann C, Mowinckel P, et al., The comparative effectiveness of tumor necrosis factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: a six-month, longitudinal, observational, multicenter study. Arthritis Rheum 2005; 52: 2506-12.
4. Kvien TK, Uhlig T, Odegard S, Heiberg MS., Epidemiological aspects of rheumatoid arthritis: the sex ratio. Ann N Y Acad Sci 2006; 1069: 212-22.
5. Kvien TK, Heiberg, Lie E, Kaufmann C, Mikkelsen K, Nordvag BY, et al., A Norwegian DMARD register: prescriptions of DMARDs and biological agents to patients with inflammatory rheumatic diseases. Clin Exp Rheumatol 2005; 23 Suppl 39: S188-94.
6. Hyrich KL, Watson KD, Silman AJ, Symmons DP., Predictors of response to anti-TNF-α therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2006; 45: 1558-65.
7. Emery P, Dorner T., Optimising treatment in rheumatoid arthritis: a review of potential biological markers of response. Ann Rheum Dis 2011; 70: 2063-70.
8. Cui J, Stahl EA, Saevarsdottir S, Miceli C, Diogo D, Trynka G, et al., Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis. PLoS Genet 2013; 9: e1003394.
9. Acosta-Colman I, Palau N, Tornero J, Fernandez-Nebro A, Blanco F, Gonzalez-Alvaro I, et al., GWAS replication study confirms the association of PDE3A-SLCO1C1 with anti-TNF therapy response in rheumatoid arthritis. Pharmacogenomics 2013; 14: 727-34.
10. Plant D, Prajapati R, Hyrich KL, Morgan AW, Wilson AG, Isaacs JD, et al., Replication of association of the PTPRC gene with response to anti-tumor necrosis factor therapy in a large UK cohort. Arthritis Rheum 2012; 64: 665-70.
11. Gomez A, Ingelman-Sundberg M., Pharmacoepigenetics: its role in interindividual differences in drug response. Clin Pharmacol Ther 2009; 85: 426-30.
12. Potter C, Hyrich KL, Tracey A, Lunt M, Plant D, Symmons DP, et al., Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis. Ann Rheum Dis 2009; 68: 69-74.
13. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al., The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
14. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL., Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
15. Fransen J, van Riel PL., The Disease Activity Score and the EULAR response criteria. Clin Exp Rheumatol 2005; 23 Suppl 39: S93-9.
16. R Development Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2011. URL: http://www.gbif.org/resource/81287.
17. Aryee MJ, Jaffe AE, Corrada-Bravo H, Ladd-Acosta C, Feinberg AP, Hansen KD, et al., Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays. Bioinformatics 2014; 30: 1363-9.
18. Du P, Zhang X, Huang CC, Jafari N, Kibbe WA, Hou L, et al., Comparison of Beta-value and M-value methods for quantifying methylation levels by microarray analysis. BMC Bioinformatics 2010; 11: 587.
19. Maksimovic J, Gordon L, Oshlack A., SWAN: Subset-quantile within array normalization for Illumina Infinium HumanMethylation450 BeadChips. Genome Biol 2012; 13: R44.
20. Leek JT, Johnson WE, Parker HS, Jaffe AE, Storey JD., The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics 2012; 28: 882-3.
21. Houseman EA, Accomando WP, Koestler DC, Christensen BC, Marsit CJ, Nelson HH, et al., DNA methylation arrays as surrogate measures of cell mixture distribution. BMC Bioinformatics 2012; 13: 86.
22. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al., limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 2015; 43: e47.
23. Tsai PC, Bell JT., Power and sample size estimation for epigenome-wide association scans to detect differential DNA methylation. Int J Epidemiol 2015. E-pub ahead of print.
24. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al., PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559-75.
25. Anderson CA, Pettersson FH, Clarke GM, Cardon LR, Morris AP, Zondervan KT., Data quality control in genetic case-control association studies. Nat Protoc 2010; 5: 1564-73.
26. Howie BN, Donnelly P, Marchini J., A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. PLoS Genet 2009; 5: e1000529.
27. Shabalin AA., Matrix eQTL: ultra fast eQTL analysis via large matrix operations. Bioinformatics 2012; 28: 1353-8.
28. Van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL., Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria. Arthritis Rheum 1996; 39: 34-40.
29. Fries JF, Spitz P, Kraines RG, Holman HR., Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 137-45.
30. Kolker E, Higdon R, Haynes W, Welch D, Broomall W, Lancet D, et al., MOPED: Model Organism Protein Expression Database. Nucleic Acids Res 2012; 40: D1093-9.
31. Boucher P, Li WP, Matz RL, Takayama Y, Auwerx J, Anderson RG, et al., LRP1 functions as an atheroprotective integrator of TGFβ and PDFG signals in the vascular wall: implications for Marfan syndrome. PLoS One 2007; 2: e448.
32. Luco RF, Pan Q, Tominaga K, Blencowe BJ, Pereira-Smith OM, Misteli T., Regulation of alternative splicing by histone modifications. Science 2010; 327: 996-1000.
33. Lev Maor G, Yearim A, Ast G., The alternative role of DNA methylation in splicing regulation. Trends Genet 2015; 31: 274-80.
34. lncRNASNP-human: lnc-LRPAP1-1:1. URL: http://bioinfo.life.hust.edu.cn/lncRNASNP/snps/rs3468.
35. Plant D, Wilson AG, Barton A., Genetic and epigenetic predictors of responsiveness to treatment in RA. Nat Rev Rheumatol 2014; 10: 329-37.
36. Reinius LE, Acevedo N, Joerink M, Pershagen G, Dahlen SE, Greco D, et al., Differential DNA methylation in purified human blood cells: implications for cell lineage and studies on disease susceptibility. PLoS One 2012; 7: e41361.
37. Baker EK, Johnstone RW, Zalcberg JR, El-Osta A., Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs. Oncogene 2005; 24: 8061-75.
38. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, et al., Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000; 343: 1350-4.